Compumedics (ASX:CMP) Gross-Profit-to-Asset % : 70.97% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Compumedics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Compumedics's annualized Gross Profit for the quarter that ended in Dec. 2023 was A$29.05 Mil. Compumedics's average Total Assets over the quarter that ended in Dec. 2023 was A$40.93 Mil. Therefore, Compumedics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 70.97%.

Compumedics Gross-Profit-to-Asset % Historical Data

The historical data trend for Compumedics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compumedics Gross-Profit-to-Asset % Chart

Compumedics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

67.57

48.56

51.74

48.15

52.09

Compumedics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															43.70	52.96	46.93	59.59	70.97

Competitive Comparison of Compumedics's Gross-Profit-to-Asset %

For the Medical Devices subindustry, Compumedics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compumedics's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Compumedics's Gross-Profit-to-Asset % falls into.

Compumedics Gross-Profit-to-Asset % Calculation

Compumedics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	21.59	/	( (41.709	+	41.182)	/ 2 )
	=	21.59	/	41.4455
	=	52.09 %

Compumedics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	29.048	/	( (41.182	+	40.682)	/ 2 )
	=	29.048	/	40.932
	=	70.97 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Compumedics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Compumedics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Compumedics (ASX:CMP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Compumedics Ltd (ASX:CMP) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

30-40 Flockhart Street, Abbotsford, Melbourne, VIC, AUS, 3067

Website

https://www.compumedics.com.au

Compumedics Ltd is a medical device company. It is engaged in the development, manufacture, and commercialisation of diagnostic technologies for sleep, brain and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of Americas, Australia and the Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.